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Summary
Proteomics is a rapidly advancing technique which
gives functional insight into gene expression in
living organisms. Urine is an ideal medium for
study as it is readily available, easily obtained and
less complex than other bodily fluids. Considerable
progress has been made over the last 5 years in the
study of urinary proteomics as a diagnostic tool for
renal disease. Advantages over the traditional renal
biopsy include accessibility, safety, the possibility of
serial sampling and the potential for non-invasive
prognostic and diagnostic monitoring of disease
and an individual’s response to treatment. Urinary
proteomics is now moving from a discovery phase in
small studies to a validation phase in much larger
numbers of patients with renal disease. Whilst there
are still some limitations in methodology, which are
assessed in this review, the possibility of urinary
proteomics replacing the invasive tissue biopsy for
diagnosis of renal disease is becoming an increas-
ingly realistic option.
Introduction
Bodily fluids in all organisms contain thousands of
proteins and peptides, which undergo disease spe-
cific changes. A deeper knowledge of the pattern of
change and the functional relevance of individual
proteins and peptides which reflect the disease pro-
cess will inevitably better define the ‘normal’ pro-
teome and provide insight into mechanisms
underlying disease. Considerable advances have
recently been made in proteomics, which allows
the study of protein expression in a tissue or
bodily fluid, and the use of urine as a source of
candidate biomarkers and potential therapeutic tar-
gets is rapidly developing. In relation to renal dis-
ease, discovery of specific peptides in the urine of
patients with renal impairment could allow the cli-
nician to make a diagnosis without the requirement
for an invasive renal biopsy. This is the ultimate goal
of urinary proteomics and is the subject of this
review article.
A specific diagnosis of renal disease may be
straightforward in the presence of pathognomonic
clinical or laboratory features; however, there are
usually several differential diagnoses and the renal
biopsy is currently the definitive investigation for
determining pathology. The diagnostic yield from a
renal biopsy has improved considerably over the last
two decades due to the use of ultrasound and auto-
mated guns,1–3 but the procedure still carries a low
but not negligible mortality rate, is associated with
significant risk of haemorrhage4 and may cause con-
siderable discomfort. Patients are also required to
remain on the ward for at least 6 h, and usually
overnight.
Several factors related to the nature of the disease
and patient status can directly impact on the effec-
tiveness of renal biopsy. Some conditions do not
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affect the kidney uniformly and the biopsy sample
may not be representative of the disease involve-
ment. The use of larger core biopsy needles and
multiple samples can circumvent this to a
degree,5,6 but there is a high-complication rates7
and the biopsy may still yield insufficient sample
to enact appropriate clinical decisions.
Preparations for the biopsy such as blood pres-
sure control and correction of coagulopathies may
delay the procedure and therefore diagnosis. Where
bleeding tendency precludes a conventional
method a transjugular approach may be required,
which has comparable yield and safety profile to
the real-time ultrasound guided automated gun
technique8 but requires personnel with expertise.
In some circumstances such as uncontrollable
blood pressure, body habitus or the presence of
other confounding factors e.g. pregnancy, the
biopsy may be contraindicated.
Some information about prognosis may be gained
from the clinical severity of the disease or degree of
chronic damage in the biopsy9 but this may not
always be a reliable estimate of the rate of deterio-
ration or outcome particularly if the specimen is
poor or non-representative. The response to treat-
ment can only be predicted by knowledge of the
disease process and the presence or absence of
known risk factors. An accurate individual assess-
ment cannot be made on the basis of the renal
biopsy alone.
A single urine specimen, sent from the ward or
clinic to the laboratory for tests which provide sen-
sitive and specific information on the disease pro-
cess and prognosis, and also predict the response to
treatment at an early stage of disease would provide
the ideal. Urine is easy to collect and simple to store
and urinary proteins are derived from both blood
and kidney.10 The role of urinary proteomics in
renal disease is now being actively explored and
the potential of this method as an alternative to the
invasive renal biopsy, together with the current
obstacles still faced, form the basis of this review.
Background
Renal handling of protein
Human urinary protein excretion is 150mg/day
protein in healthy normal individuals;11 of the con-
stituent proteins 70% are derived from the kidney
and 30% originate in the plasma.12,13 Proteins of
molecular weight <40 kDa are freely filtered by
the glomerulus and almost all are reabsorbed in
the early proximal tubule by active transport path-
ways involving receptor-mediated endocytosis.14
When the glomerular filtration barrier is disrupted
in glomerular diseases, larger proteins appear in
the urine in considerable quantities giving rise to
glomerular proteinuria.
Tubular epithelial cells secrete low molecular
weight soluble proteins, including Tamm-Horsfall
proteins and ß2 microglobulin. When damaged,
this process is disrupted (e.g. interstitial nephritis,
acute tubular necrosis, Fanconi syndrome), and con-
centrations of these proteins increase in the urine,
together with reduced uptake of filtered low molec-
ular weight proteins. ‘Tubular proteinuria’ usually
produces less total urinary protein than glomerular
disease (<2 g/day) due to lower molecular masses of
the proteins affected. In healthy individuals tubular
proteins make up 19% of total urinary protein.15,16
Urinary sediment proteins account for 48% of
total urinary protein from sloughed epithelial
cells,15,16 including podocytes, tubular cells and
lower urinary tract cells which are shed into the
urine, especially in first void specimens. These
increase in inflammatory conditions or in associa-
tion with malignancy of the urinary tract. The
remaining 3% of urinary protein consists of exo-
somes originating from cells from the tubular epithe-
lial and the urogenital tract, which can be isolated
by ultracentrifugation as they remain in the
supernatant.15,16
Over-flow proteinuria may occur in disease states
associated with enhanced synthesis of new small
proteins that are freely filtered and overload tubular
reabsorptive capacity. Examples include light chain
proteinuria, haemoglobinuria in haemolysis, and
rhabdomyolysis. Saturation of tubular reabsorption
also occurs in glomerular disease, due to the disrup-
tion of the glomerular filtration barrier, when the
plasma proteins which gain access to the proximal
tubule overwhelm reuptake mechanisms.
Available techniques for detecting or quantifying
total urinary protein content, together with other
standard urine assays for proteins are shown in
Table 1. None of these routine tests (other than
that for immunoglobulin light chains) identifies or
quantifies individual proteins within urine.
It should be appreciated, that in addition to the
abundance of proteins identified in the urine, ana-
lysis is complicated by post-translational modifica-
tion e.g. advanced glycation in diabetes17 and splice
variants, which may nonetheless provide valuable
aids to disease diagnosis and prognosis prediction.
These are detectable by a difference in protein
mass, and are identifiable by mass spectrometry.
So far more than 1500 different proteins have been
characterized in normal healthy individuals’ urine.13
Separation, differentiation and quantitation of con-
stituent proteins can be achieved by proteomics.
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An overview of current proteomic
techniques
The proteome is defined as the profile of the proteins
within a bodily fluid, tissue or cell and the pepti-
dome refers to the lower molecular weight peptides
in a sample. Whilst this review focuses on the uri-
nary proteome similar principles also apply to the
urinary peptidome, although sample preparation
steps may vary. Figure 1 shows a general approach
to urinary proteomic methods. Currently there is
no universal approach for urine collection and
preparation for proteomic analysis and this is the
focus of the Human Kidney and Proteome Project
(http://www.hkupp.org/)/World Human Proteome
Organisation (http://www.hupo.org/) and European
Kidney and Urinary Proteomics (http://
www.eurokup.com).
Sample collection
The volume, protein composition and protein con-
centration of urine shows considerable diurnal var-
iation. No ideal time of day to collect urine
specimens for proteomics has been identified, but
it is preferable to obtain specimens after controlled
bed rest or at least at the same time of day to min-
imize variation from position or effects of exercise.18
First void urine tends to be more concentrated with a
higher yield of proteins and two-dimensional elec-
trophoresis (2-DE) proteomic analysis of samples
from healthy individuals has shown all proteins
found in urine collected over a 24-hour period to
be present in first void urine,19 although contamina-
tion in first void samples from cells from the lower
urinary tract and bacteria introduces another vari-
able;20 and, in women, proteins are present in the
early morning which are not found at other times of
day.21 The current consensus is to use random mid-
stream urine specimens, other than the first morning
void, to mitigate contamination by bacteria har-
boured in the urinary tract.
Some intra-patient variability in the urine pro-
teome has been previously observed,22 but other
investigations have identified only minor variations
in samples collected for up to a year.19,23 Individual
fluctuations seem to be minimally affected by diet
and exercise.24 The relative influence of exogenous
and endogenous factors needs further exploration,
but should be considered when planning protocols
and in interpretation of data.
Sample storage
An advantage of urinary proteomics is that the ana-
lytical reproducibility of the urine proteomic profile
is unaffected by long term freezing,25 remaining
stable for several years, even when stored at
208C.26,27 Examination of the role of centrifuga-
tion before and after freezing, the impact of freeze-
thaw cycles, the effect of temperature and the use of
protease inhibitors28,29 has suggested that samples
should ideally be centrifuged prior to storage at
808C to reduce contamination by proteins leaking
cellular debris and bacteria.16 Most laboratories
have not adhered to this standard and its advantages
Table 1 Current methods for assessing proteinuria
Test Sensitivity Method Advantages Disadvantages
Urine Dip >250mg/l Binding of urine protein
to tetrabromophenol
blue
Quick and cheap Lower limit of sensitivity,
some proteins do not
bind e.g. Bence–Jones
protein
24 h urine
collection
30mg/24 h Biuret method Current gold-standard Inaccurate due to
incomplete collection,
inconvenient and time
consuming
Protein:creatinine
ratio
0.02mg/mmol Corrects for variation in
urinary concentration
due to hydration
Simple, cheap and
quick, replacing 24 h
urine collection
Only measures total
protein
Immunoglobulin
light chains
0.04 g/l Urine protein electro-
phoresis and immuno-
fixation or
immunoassay-based
free light chain assay
Able to detect at low
levels
Expensive and disease
specific
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remain to be proven. In addition, centrifugation may
result in the loss of urinary protein,30 but this may be
an acceptable ‘sacrifice’ to obviate sample contam-
ination. With or without centrifugation, samples
should be stored in multiple aliquots and freeze-
thaw cycles minimized to four or less to preserve
protein stability25 (e.g. IgG and alpha-1 antitryp-
sin31). Reproducibility is maintained in samples
stored for four to six hours at room temperature,23,32
or for up to three days at 48C.25 Boric acid
(2–20mM) or sodium azide (0.1–1mM) can be
added to retard bacterial overgrowth, with higher
concentrations recommended for 24 h collections.28
Without preservatives, bacterial overgrowth can
occur within non-centrifuged samples after eight
hours at room temperature, or 20 h at 48C.29
Protease inhibitors were previously recommended
for preservation12 but may interfere with mass spec-
trometry analysis and small molecular weight inhi-
bitors can bind to peptides altering the isoelectric
point.33,34 Urine with low protein concentration
contains only modest amounts of protease activity
which is unlikely to affect sample stability.
However, the abundance and effects of proteases
in urine with higher protein concentrations needs
further investigation and could have implication
for the study of the proteome in patients with signif-
icant proteinuria.
The pH of urine, which can vary from 5 to 8,
influences enzyme activity and therefore protein
cleavage.10 In a study of renal transplant rejection
the urine pH was lower with active rejection, play-
ing a permissive role in the action of endogenous
proteases in cleavage of ß2-microglobulin, leading
to greater abundance of different ß2-microglobulin
fractions.35 The effect of pH on posttranslational
modification of urinary proteins is poorly under-
stood. It is likely to be significant and should routi-
nely be reported in urinary proteomics studies.
Sample preparation
Appropriate preparation of samples is strongly
dependent on the proteomic techniques to be used
and should be factored into the study design. Some
of the more common approaches are discussed
below.
Protein extraction and salt removal from
urine samples
Isolating or concentrating urinary proteins may be
essential in low concentration specimens, particu-
larly for less sophisticated gel-based studies.
Numerous methods have been compared including
precipitation with organic solvents, centrifugal filtra-
tion, lyophilization and ultrafiltration but with vary-
ing results. In one study lyophilization afforded the
greatest quantitative protein yield, but lowest quali-
tative yield, whereas acetonitrile precipitation gave
the best qualitative yield.22 In contrast, others found
Figure 1. Overview of urinary proteomics: examples of simple workflow for protein identification. Proteins are extracted
from urine, optionally immunodepleted of some abundant proteins including albumin and immunoglobulins, and enzyma-
tically digested (usually with trypsin). The resulting peptides are fractionated by string ion exchange before liquid chroma-
tography and tandem mass spectrometry (LC-MS/MS); precursor peptides and fragment ion masses are anlysed by complex
search programmes to identify proteins from genomic databases.
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that centrifugal filtration was superior in terms of
ease of analysis and consistency of protein yield
compared with dialysis/lyophilization and organic
salt precipitation.36 Reverse phase extraction has
also been shown to be effective in specimen con-
centration as well as for desalting urinary peptides
and segregating lower-molecular weight proteins.18
Different proteins appear to be lost with each of the
preparative techniques and therefore a combination
approach is most likely to give the complete pro-
teome. These methods simultaneously remove
sodium, potassium and urea from the sample,
which otherwise could affect the efficiency of enzy-
matic proteolysis, for example trypsin activity.
Albumin removal
The dynamic range of plasma proteins in the urine is
estimated to be of 12 orders of magnitude of con-
centration, ranging from high-abundance albumin
(in renal disease) and uromodulin to low-abundance
cytokines.37 Even in urine from healthy individuals
there are many free amino acids and many low
molecular weight peptides (<250 Da).38 The con-
centration of albumin is a particular problem in
nephrotic syndrome when it may be ten-fold
higher than normal. The most advanced mass spec-
trometer (MS) can probe through proteomic depths
of about 8 orders of magnitude, but to distinguish
lower abundance proteins specific sample enrich-
ment is required. No single approach can yet
reveal the entire urinary proteome but complemen-
tary application of different protein separation and
MS techniques can provide a more comprehensive
analysis.23
The removal of albumin by immunoprecipitation,
affinity capture or protein size fraction improves the
identification of low abundance proteins.13,39–41
However, albumin depletion is not necessarily
desirable as albumin itself or other abundant pro-
teins may reveal invaluable information about the
disease process. For example, in nephrotic patients
a characteristic repetitive fragmentation pattern of
urinary albumin has been identified,42 and a disease
specific albumin fragment has been isolated in Type
2 diabetics with low-level microalbuminuria who
may be at risk of disease progression.43 Furthermore,
lower abundant proteins may be bound to albu-
min and co-depleted. Ultracentrifugation with
detergents and chaotrophic agents (e.g. urea and
SDS) can be employed to disrupt protein–protein
interactions, but these interfere with MS and
2-DE methods and necessitate additional sample
clean-up.44
Concentration and normalization
The variable dilution of urine needs to be factored
into proteomic analysis to enable accurate quantifi-
cation.45,46 Some laboratories standardize speci-
men concentration on the basis of creatinine
(e.g. 50 nmol/100 ml)47,48 which is excreted at a rel-
atively constant rate,48 except in renal disease,
which could obviously confound interpretation. If
the specimen is concentrated proportionally to crea-
tinine different amounts of proteins are analysed
which will affect the profile identified, but this
method does allow absolute quantification and
therefore direct comparison of samples. Another
approach is to study identical total protein loads,
and therefore only relative amounts of individual
proteins can be compared. Jantos-Siwy et al. have
recently defined a series of ‘house-keeping’ collagen
fragments that allow relative quantification of bio-
marker peptides between samples in patients
with chronic kidney disease (CKD). These endog-
enous peptides were superior to exogenous iso-
tope-labeled peptide standards for biomarker
quantification.49
Trypsin digestion
For the purposes of mass spectrometry, proteins are
typically digested by the endoprotease trypsin to
generate proteolytic peptides. Trypsin cleaves pro-
teins after the basic arginine and lysine residues, and
the resulting tryptic peptides generally possess a
positively charged C-terminal arginine or lysine resi-
due. The presence and localization of the positively
charged residue facilitates ionization and fragmen-
tation of the peptide during mass spectrometry; thus
trypsin is the enzyme of choice for most proteomic
applications and is favoured over proteases that
cleave at other residues. To improve efficacy of
digestion and to achieve total protein lysis, proteins
are usually first reduced, to cleave disulfide bridges,
and free cysteines are alkylated in order to prevent
the reformation of disulfides, or other undesired
reactions.
Protein/peptide separation
The enormous differences in protein content and
abundances in biological matrices such as urine
and plasma renders it impossible to analyse the pro-
teome comprehensively by MS, without prior frac-
tionation.10 Fractionation can be performed at the
protein level or the peptide level, or both, depend-
ing on sample complexity. Protein separation is
commonly achieved using 1D-SDS–PAGE, 2-DE,
or capillary electrophoresis (CE); 1D-SDS–PAGE
separates proteins according to molecular mass,
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CE by differences in isoelectric point and 2-DE by
both molecular mass and isoelectic point. These
methods have the advantage of separating many
lower abundance proteins from higher abundance
proteins to improve proteomic coverage and
depth. Peptide separation after proteolytic digestion
is typically performed using reverse phase-high per-
formance liquid chromatography (RP-HPLC) and/or
strong cation exchange (SCX), which separate pep-
tides based on hydrophobicity and charge state,
respectively. Both methods can be linked online to
MS processing. Achieved by whatever means, frac-
tionation provides enriched sub-populations of pep-
tides for introduction to the MS.
Two-dimensional electrophoresis, which has
been in use for several decades, requires isolation
of protein spots and physical dissection before enzy-
matic digestion and entry into the MS for ionization.
It is labour intensive and can analyse only 70–420
protein spots per gel, compared to 400–2000 poly-
peptides in a single run of CE–MS,50–52 but does
allow the detection of some large proteins which
may not elute in a defined peak or which precipitate
during HPLC. More recently, 2D difference gel elec-
trophoresis (2D-DIGE) has been developed and used
successfully in urine.53 It utilizes fluorescent dyes
and internal standards for more accurate quantifica-
tion and comparison of two samples, as well
improved reproducibility. Smaller peptides (<10
Da), however, are not detectable.26,54
Mass spectrometry
Each mass spectrometer consists of an ion source, a
mass analyser that measures the mass-to-charge
ratio (m/z) of the ionized analytes and a detector
that registers the number of ions at each m/z
value. Different ionization sources include matrix
assisted laser desorption/ionization (MALDI) and its
variant surface enhanced laser desorption/ionization
(SELDI), which employ an organic acid matrix to
sublimate and ionize analytes with laser pulses,
and electron-spray ionization (ESI) which involves
spraying voltage charged analyte solutions to deso-
lvate and ionize the analytes. Different mass analy-
sers include ion trap (IT), time-of-flight (TOF),
quadrupole (Q) and Fourier transform ion cyclotron
resonance (FT-ICR) devices. Sequential combination
of two mass analysers, known as MS/MS or tandem
mass spectrometry, can also be performed, for
example using QQQ, Q-TOF and TOF/TOF config-
urations. Initial selection of a precursor peptide ion
of interest by the first mass analyser is immediately
followed by the fragmentation of the precursor ion,
most often by collision induced dissociation with an
inert gas such as argon or nitrogen, and subsequent
detection of the resulting daughter fragment ions by
the second mass analyser. MS/MS experiments for
individual precursor ions occur on millisecond time-
scales and rapidly generate peptide sequence infor-
mation to complement the mass of the selected
precursor peptide. The different mass analyser con-
figurations can be alternately combined with the
ionization sources although most commonly
MALDI is coupled with TOF (MALDI-TOF and
MALDI-TOF/TOF) and ESI with Q (ESI-QQQ and
ESI-QTOF). More recent instruments include linear
ion trap instruments which have expanded capabil-
ity over traditional QQQ analysers, including MS/
MS/MS functionality and superior sensitivity.
Additional coupling of the linear ion trap to the
recent Orbitrap mass analyser further enables the
simultaneous acquisition of selected ions with extre-
mely high resolution and mass accuracy. The differ-
ent MS platforms employed in proteomics have
been comprehensively reviewed by others.26,55
Bioinformatics and data analysis
Proteins may be identified after MS analysis by two
common methods. The first and older method of
peptide mass fingerprinting (PMF) involves matching
the observed experimental peptide masses against
theoretical peptide masses calculated from in silico
digestion of protein databases e.g. for MALDI-TOF.
The confidence in protein identifications obtained
by PMF is strongly dependent on the mass accuracy
of the observed peptide ions and the complexity of
the analyte. Although it is possible to identify pro-
teins confidently in simple mixtures of a few pro-
teins, the additional peptides observed after
digesting more complex samples compromises con-
fidence in protein identification. The advent of
tandem mass spectrometry enabled a second
method for confident identification of peptides and
proteins based on the peptide mass combined with
fragment ions that elucidate sequence information.
The precursor peptide and fragment ion masses are
analysed by complex search programs, such as
Mascot (http://www.matrixscience.com) and
Sequest (http://www.thermo.com), to identify and
score the observations against theoretical results
generated by in silico digestion and fragmentation
of proteins derived from genomic databases.56,57 A
probability scored protein ‘hit list’ can then be con-
structed based on the number and confidence of the
identified peptides. The success of the database
interrogation is dependent on the accuracy of the
database to reflect the true biology, and the input
of search parameters to account for appropriate
post-translational modifications. For instance,
search results can be adversely affected if
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polymorphisms or mutations are not included in the
database sequence, and in the latter case peptides
modified by phosphorylation, alternative splicing
or endogenous proteolytic degradation will be
overlooked if unaccounted for. However, recent
advances in bioinformatics and computing power
are beginning to address some of these issues by
enabling de novo search strategies to account for
unanticipated polymorphisms, proteolysis or other
sequence modifications.58
The importance of bioinformatics in studies of uri-
nary proteomics cannot be underestimated and with
the creation of substantive proteomic databases,
sophisticated computer hardware and software are
required. Individual MS runs can identify hundreds
to thousands of proteins, any of which could be
potential biomarkers. Analysis generally focuses on
small subsets of the data exhibiting obvious differ-
ential changes between control and case samples
rather than evaluation of the entire dataset.59 A gen-
eral approach is to develop an algorithm for analysis
in a ‘training set’, which incorporates the most
prominent differentially expressed proteins for vali-
dation against a ‘validation set’ for diagnostic utility;
in some cases validation may involve measuring the
new candidate biomarkers using a conventional
technique such as ELISA or immunohistochemistry60
or the development of MS based multiple reaction
monitoring (MRM) assays for high throughput
analysis.
Appropriate statistical tests must be applied with
clinical a priori hypotheses, including the need for
suitable corrections for application of multiple
testing (such as Bonferroni tests).61 Figure 2 shows
a general approach to biomarker development and
clinical application.
Role of urinary proteomics in
a clinical setting
Traditionally approaches towards identifying poten-
tial useful urinary biomarkers have evolved from our
understanding of pathophysiology of diseases—i.e.
they are ‘hypothesis driven’. Increasingly, urinary
proteomics is used to discover potential bio-
markers for both diagnosis and prognosis of renal
disease, which indirectly give insight into patho-
genic processes—i.e. an approach which is ‘hypoth-
esis generating’. The advantages of urinary
proteomics for disease diagnosis are described in
Table 2.
Diagnosis
Proteomic biomarkers which are to be suitable as
non-invasive alternatives to renal biopsy, must exhi-
bit differential detection in the urine of patients with
and without disease. They must be specific to the
disease in question and ideally should be detected
early in disease onset to maximize the benefits of
therapeutic intervention. The urinary proteomes of
both glomerular and interstitial diseases have been
described in small numbers of patients and are now
moving into a validation phase.
One of the first proteomic studies in renal disease
was reported by Lafitte et al. who compared 2-DE
Proteomic analysis
Biomarker Candidates
Prognosis Diagnosis Response to 
Treatment
Discovery
Validation
Pathophysiology
Studies
Biomarker Panel
Development Phase Clinical Use
Patient Sample
Disease 1 
Biomarker Panel
Disease 2 
Biomarker Panel
Disease 3 
Biomarker Panel
Renal Biopsy
No Diagnosis
Standard 
Laboratory Tests
Clinical 
Information
Prognosis Diagnosis Response to 
Treatment
Selection 
of
Biomarker 
Panels
Figure 2. Schema of translation of urinary proteomics into clinical practice.
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analysis of urine from healthy controls with four
patients with incipient diabetic nephropathy, mini-
mal change disease, myelomatous kidney and prox-
imal tubular acidosis. A stable map for healthy
controls was established and there were distinct dif-
ferences between the patients with renal disease.19
In a subsequent study, the urine from patients with
other proteinuric glomerular diseases including
focal segmental glomerulosclerosis (FSGS) (n=10),
minimal change (n=16) and membranous nephro-
pathy (n=18) were analysed by CE-MS and com-
pared with control (n=57).24 One hundred and
three proteins were identified in >90% of healthy
individuals’ urine, which allowed the definition of a
‘normal’ urinary proteome, and when compared
with profiles of patients with disease enabled the
correct classification of 92.9% of patients with mem-
branous nephropathy and 71.4% of patients with
minimal change or FSGS. Further potential biomar-
kers for membranous nephropathy have also been
identified in the urine using both SELDI and CE-MS
approaches.62
A similar study identifying diagnostic biomarkers
using 2DE and MALDI-TOF-MS with a training set of
16 patients and validation set of 16 patients cor-
rectly identified patients with FSGS, lupus nephritis,
membranous nephropathy and diabetic nephropa-
thy with sensitivities of 75–86% and specificities of
67–92%.63 Other candidate biomarkers for diagno-
sis of FSGS, membranous nephropathy, minimal
change disease, IgA nephropathy and diabetic
nephropathy have also been identified with CE/ESI-
QTOF-MS.64
Pooled urine from 13 patients with IgA nephropa-
thy analysed with 2-DE showed differential expres-
sion of proteins (82 spots over-expressed and 134
spots under-expressed) compared with 12 normal
healthy individuals. Fifty-nine proteins which signif-
icantly varied between patients and controls were
subsequently identified by MALDI-TOF.65 Further
definition of the urinary proteome of 45 patients
with IgA nephropathy, using a CE-MS approach,
had a sensitivity of 100% and specificity of 90%
when compared to 57 healthy controls, 100% sen-
sitivity and specificity when compared to patients
with diabetes, minimal change disease and FSGS
and a sensitivity of 77% and specificity of 100%
when compared to patients with membranous
nephropathy.51
Larger studies are now being performed including
a CE-MS analysis of 402 patients with various renal
disorders and 207 controls.66 This has allowed the
definition of a characteristic pattern of renal damage
and IgA nephropathy. Furthermore, blinded analysis
of an additional cohort of patients with different
aetiologies of IgA nephropathy allowed the distinc-
tion between some subgroups.66
Whilst offering exciting potential, the diagnostic
accuracy of these techniques is not yet sufficient to
replace the renal biopsy. Studies are limited by size
and assessment of a potentially restricted compo-
nent of the urinary proteome. In addition, further
analysis needs to be performed using complemen-
tary MS techniques to define more comprehensively
the proteins that constitute the individual fingerprint
of renal pathology for each disease, and to improve
the sensitivity and specificity of each battery of tests.
Lupus nephritis
Disease activity in lupus nephritis is a clinical sce-
nario which may require multiple biopsies through-
out the disease course to guide the initiation and
escalation of treatment. The International Society
of Nephrology/Renal Pathology Society (ISN/RPS)
class of lupus nephritis may change with time
and ideally a test should also be able to determine
this as well as activity and progression of the
disease.
Table 2 Advantages and disadvantages of renal biopsy and urinary proteomics
Renal Biopsy Urinary Proteomics
Invasive Easily available
Resampling difficult Resampling same day possible
Requires admission Can be used in clinic
Blood pressure and coagulation may delay procedure Immediately available
Patient habitus may make impossible Only impossible in anuric patients
Inadequate sampling Only 10ml urine required
No guide to treatment Response to treatment predicted
Minimal guide to prognosis Prognostic information possible
Cheap processing techniques, but requires hospital
admission
Currently expensive until panels of biomarkers are
available
Current gold standard Sensitivity and specificity continually improving
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Mosely et al. compared the urinary proteome of
26 patients with active lupus nephritis (defined by
renal biopsy, or the presence of predefined rise in
creatinine, proteinuria or the presence of new hae-
maturia) and 49 patients with inactive disease using
SELDI-TOF.47 These authors identified differentially
expressed proteins. It was possible to classify
patients correctly according to disease activity with
both a sensitivity and specificity of 92%. On further
scrutiny of four wrongly classified inactive patients
there was some evidence of incipient disease activ-
ity. Similarly, two patients incorrectly classified as
active, on post-analysis review were becoming inac-
tive according to biochemical parameters, suggest-
ing that the novel urinary biomarkers may also
be capable of detecting early stages of relapse or
recovery. Sub-analysis of ISN/RPS classifications
was not made.
A study of children with lupus nephritis identified
an eight-biomarker proteomic signature for SLE
nephritis using SELDI-TOF-MS. The protein expres-
sion differed between ISN/RPS classes, but did not
reach statistical significance, although the biomar-
kers were able to identify clinical and biochemical
disease activity correctly.67 One limitation was a
median delay of 9 months between biopsy and
sample collection, potentially reducing discrimina-
tion between classes.
Oates et al. collected urine samples immediately
prior to biopsy in 20 patients investigated for lupus
nephritis, which were analysed with 2-DE. The sen-
sitivity and specificity for the ISN/RPS classes were
class II 100%, 100%; III 86%, 100%; IV 100%,
92%; and V 92%, 50% according to a trained arti-
ficial neural network.68 Nine patients had character-
istics of more than one class.
Whilst larger studies are needed to develop tests
which can be used routinely in the diagnosis and
monitoring of lupus nephritis, these preliminary
studies hold promise for obviation of serial biopsies
in the future.
Allograft rejection
The detection of acute rejection is a common indi-
cation for biopsy of a renal transplant in the first
year, in which renal tubular damage is a principal
feature. Clarke et al. examined the urinary proteome
of 17 renal transplant patients with biopsy proven
acute rejection and 15 with stable allograft function.
Using independent statistical analysis they identified
five peaks with the greatest discriminatory function
(6.5, 6.6, 6.7, 7.1 and 13.4 kDa). Two separate bio-
markers (3.4 and 10 kDa) gave sensitivity and spe-
cificity of 83% and 100%, respectively.69
A similar study including 18 patients with acute
allograft rejection, 22 with stable allograft function,
five patients with urinary tract infection and 32
normal controls defined two different profiles
(5270–5550 and 10530–11 000 Da) for differentia-
tion between patients with acute rejection and
patients with stable function or normal controls. In
two patients the profile switched from acute rejec-
tion to stable and visa versa.21 The proteins have
subsequently been identified as cleaved forms of
b-2 microglobulin, which were present with higher
levels of intact b-2 microglobulin and aspartic pro-
teases (which cleave b-2 microglobulin).35 Oetting
et al. have subsequently confirmed the use of
b-2 microglobulin as a biomarker for rejection.70
A further study demonstrated proteins with masses
of 4756.3, 25 665.7 and 19 018.8 Da in renal trans-
plant patients with acute rejection, which allowed
distinction from patients with stable organ function
in >90% of cases with a sensitivity of 90.5–91.3%
and a specificity of 77.2–83.3%.71 Subsequent
identification of peaks detected a reduction in
beta-defensin-1 and an increase in alpha-1 antichy-
motrypsin in patients with acute rejection.72
Perhaps not surprisingly in view of the complexity
of the proteome and the variation in methodology,
the profiles were different in the three studies and no
two studies have described the same discriminatory
peaks or proteins, despite all groups using SELDI-
MS. This is likely to represent differences in
sample collection, storage and preparation or
immunosuppression regime which has been shown
to affect the urinary proteome,73 but is more likely to
be due to SELDI laser and detector performance and
the use of different chip surfaces. Urinary proteo-
mics have also been able to discriminate between
urinary tract infection and acute allograft rejection
and between tubular and vascular rejection.73 These
new biomarkers should be validated by the
development of appropriate ELISAs to allow repro-
ducibility and quantification, given the current intra-
sampling variability of SELDI-MS. Thus there is the
potential to create a diagnostic panel with enhanced
sensitivity and specificity which would allow a
reduction in the need for renal biopsies in the post
transplant period.
Quintana et al. have examined the urinary pro-
teome of 39 patients with chronic allograft nephro-
pathy (CAN) and 32 controls by label free
quantitative LC-MS/MS followed by MRM valida-
tion. Specific peptides derived from uromodulin
and kininogen were more abundant in controls
than patients and differential expression of two
ions diagnosed CAN in virtually all cases.74 They
propose that these biomarkers could form the basis
of a biopsy-free urine test for the early diagnosis of
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CAN and will facilitate a more rapid introduction of
targeted and personalized immunosuppressive
regimes to improve long-term graft outcome.
Predictors of disease/prognosis
Acute kidney injury
Acute kidney injury (AKI), formally known as acute
renal failure, is a clinical problem associated with
high mortality and morbidity which has been exten-
sively studied.75 The current method of diagnosis is
to monitor serum creatinine, an unreliable indicator
during acute changes in renal disease, as a steady-
state equilibrium must be achieved before creatinine
can provide a reliable measure of renal function.
Creatinine is also influenced by other variables
including sex, age, muscle mass and metabolism,
drugs and hydration. Other approaches include the
detection of casts and fractional excretion of
sodium, which are both non-specific and insensitive
for early detection of AKI. Consequently many cases
are detected late resulting in an unacceptable delay
for appropriate therapeutic intervention. The goal for
urinary proteomics is to define a panel of tests,
which will allow early identification of patients at
risk, in order to institute rapid and aggressive
treatment.
Nguyen et al. identified biomarkers with m/z of
6.4, 28.5, 43 and 66 kDa, using SELDI-TOF MS
which were elevated in the urine of children with
ischemic kidney injury (defined as a rise in creati-
nine >50%) following cardiopulmonary bypass sur-
gery when compared with preoperative samples.
A combination of these three markers predicted
the development of AKI at 2 h in 100% of patients,
despite serum creatinine not rising for 2–3 days after
the procedure.76
Using a rat model of sepsis-induced AKI and
2-DE/MALDI-TOF analysis, Molls et al. identified
urinary peptides that were upregulated in AKI
including albumin, aminopeptidase and neutrophil
gelatinase associated lipocalin (NGAL) when com-
pared with animals, which did not develop AKI.77
Other urinary proteins were decreased, including
uromodulin (Tamm-Horsfall mucoprotein), serum
protease inhibitors and meprin-1-alpha (a brush
border enzyme). Meprin-1-alpha was also reduced
in the rats with AKI when analysed by western blot-
ting. The administration of actinonin (which inhibits
meprin) partially resolved the sepsis-induced AKI,
suggesting a potential role for meprin in pathogen-
esis, and a strategy for therapeutic intervention. This
urgently needs to be evaluated in humans and high-
lights an important role for the urinary proteomics in
identifying novel pathophysiological pathways and
targets for treatment.
Other studies utilizing microarrays and ELISAs
have identified higher concentrations of Kidney
injury molecule 1(KIM-1), IL-18, cystatin C, 1-micro-
globulin, Gro-&agr in the urine of patients with
incipient AKI75,78,79 and have confirmed the role
of urinary NGAL as a marker of AKI post cardiopul-
monary bypass,80 delayed graft function81 and as a
predictor of severity in haemolytic-uremic syn-
drome82 and contrast induced nephropathy.83
More recently, urinary active hepcidin detected by
SELDI-TOF has also been proposed to be an early
marker of AKI in patients after cardiopulmonary
bypass suggesting a role for iron sequestration in
modulating AKI.84 A combination of these tests
with candidate biomarkers from proteomic discov-
ery needs to be applied to a clinical setting in order
to define a panel of markers, which when combined
in an algorithm would have increased specificity
and sensitivity than a single test alone.
Chronic kidney disease
Currently in the US 20-million people suffer from
kidney disease, of which 60 000 die due to end
stage renal failure (http://www.asn-online.org).
Early predictors of CKD are urgently needed to
enable appropriate monitoring and timely treatment
in order to minimize disease burden especially since
the deterioration in renal function can be reduced if
aggressive management is instituted early. Serum
creatinine and urine protein are the standard
methods for detecting progression, but there are no
current prognostic biomarkers other than microalbu-
minuria, which already represents structural renal
damage, that might allow preventative treatment to
be introduced.
The urine NGAL concentration shown to correlate
with future changes in serum creatinine in a pilot
study of 78 patients with CKD.78 Similarly liver-
type fatty acid-binding protein (L-FABP) is signifi-
cantly higher in the urine of CKD patients with
progressive disease than those with stable disease.85
The use of proteomics in this clinical setting would
potentially allow the identification of many more
biomarkers, which together with clinical indices
and pre-existing markers of renal function could
give an individual prediction of deterioration in
renal disease. Nephrologists could then focus on
those patients at highest risk, whereas patients with
stable disease could be managed in primary care.
Diabetic nephropathy
Meier et al. studied 44 adolescents with type 1 dia-
betes for more than 5 years compared with age-
matched healthy controls and identified a urinary
proteome with CE-MS typical for patients with
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diabetes without microalbuminuria, which may
represent early diabetic vascular dysfunction and
subtle changes in the glomerular filtration barrier
due to increased protein glycation, as well as 88
polypeptides which were present in differential
amounts in patients with albumin:creatinine ratios
>35mg/mmol.52 The predictive value of individual
polypeptides, which are not present in healthy con-
trols, need to be evaluated further.
Unlike type 1 diabetes, the development of pro-
teinuria in type 2 diabetes may not be indicative of
diabetic nephropathy and may be due to other
causes such as hypertensive nephropathy. The
development of biomarkers for both diagnosis and
prediction of those at risk of diabetic nephropathy in
patients with type 2 diabetes would be invaluable to
allow appropriate intervention and reduce the need
for a renal biopsy in some individuals. Proteomic
analysis of the urine of 112 patients with type 2
diabetes and healthy controls has allowed the defi-
nition of a diabetic, non-proteinuric pattern. In addi-
tion a distinct pattern has been noted in patients
with microalbuminuria (>100mg/l), in 35%
of patients with low levels of microalbuminuria
(20–100mg/l) and in 4% of patients with no albu-
minuria. Patients in these latter two groups were
more likely to suffer retinopathy and therefore statis-
tically have a higher risk of developing nephropa-
thy.43 The presence of the characteristic
polypeptides identified (insulin-like peptide 3, uro-
modulin and an albumin fragment) may indicate a
population at risk of incipient nephropathy who
require early intervention to prevent disease
progression.
A different group have examined the urine of 100
patients with type 2 diabetes using 2-DE followed by
MALDI-TOF. Proteins identified included zinc
alpha-2 glycoprotein, alpha-1 acid glycoprotein,
alpha-1 microglobulin and IgG, and these could
also be used as markers for the early detection of
diabetic nephropathy.86 Furthermore, Rao et al.
have identified six proteins in addition to zinc
alpha-2 glycoprotein which were found to be up-
regulated in diabetic nephropathy and four proteins
which were progressively down-regulated using
2D-DE and LC/ES-MS/MS.53
A nested case–control study of 62 Pima Indians
with type 2 diabetes has confirmed a 12-peak urine
proteomic profile, which correctly predicted the
development of nephropathy over 10 years in 89%
in a training set (n=14) and 74% in a validation set
(n=17), with sensitivities and specificities of 93%
and 86%, and 71% and 76%, respectively.87
However, the cases and controls could not be
matched for HbA1C due to the sample size, which
may have influenced the proteomic signature and
hence outcome.
Rossing et al. have recently described a panel of
40 biomarkers which identified patients with diabe-
tes from healthy individuals in a large cohort with
89% sensitivity and 91% specificity. They also
describe a profile, which accurately diagnosed
nephropathy in patients with diabetes with 97% sen-
sitivity and specificity and identified those with
microalbuminuria who progressed to overt nephro-
pathy over a 3 year period.88
Given the exponential rise in diabetic nephropa-
thy in the last decade, identification of those at risk
would allow early intervention and have major
implications for health economics. Urinary proteo-
mics clearly has an important role to play in achiev-
ing this goal.
Prediction of response to treatment
and disease monitoring
The response to steroids is an important predictor of
prognosis and determinant of biopsy in paediatric
idiopathic nephrotic syndrome. Two studies have
examined the urine of children with steroid sensitive
and steroid resistant nephrotic syndrome with
SELDI-TOF-MS. One group identified ß2 microglo-
bulin as having diagnostic accuracy in 95% of chil-
dren with steroid-resistant disease, together with five
other distinct peaks, which distinguished these chil-
dren from those with steroid sensitive disease.89
Another group identified a protein of mass 4144
Da, which reliably classified 25 patients with steroid
sensitive and resistant disease.90 These studies need
validating in larger cohorts, and the predictive value
of algorithm, a combining these candidate biomar-
kers should be explored.
The prevention of progression of IgA nephropathy
is related to control of hypertension and proteinuria.
Standard treatment for this condition in the presence
of these complications is the use of angiotensin-con-
verting enzyme inhibitors (ACEi) or angiotensin II
receptor blockers, but some patients do not respond
and alternatives are sought. A study of urine of 18
patients with IgA nephropathy who had been treated
with long term ACEi identified three proteins (kini-
nogen, inter-alpha-trypsin-inhibitor heavy chain 4
and transthyretin), using 2-DE then nano-HPLC-
ESI-MS/MS analysis, which were excreted differently
in responders to ACEi when compared to those who
had not responded.91 A reduction of daily protei-
nuria >50% and evidence of stable renal function
over time were used to classify patients as respon-
ders. In a prospective study, kininogen was mea-
sured in 20 patients with biopsy-proven IgA
nephropathy, before starting any therapy. Very low
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levels of kininogen urine excretion were predictive
of an inadequate or absent clinical response to ACEi
therapy of after 6-month follow-up.91 The use of
proteomics in this capacity would guide the early
initiation of individualized treatment, which is not
possible from information gained from the routine
tissue biopsy.
In a randomized double-blinded study, patients
with diabetic nephropathy were given varying
doses of candesartan. Proteomic analysis of the
urine before and after treatment revealed a change
in 15 out of 113 proteins previously found to be
specific for diabetic nephropathy,92 providing addi-
tional evidence for the potential role of proteomics
in monitoring individual response to disease.
Understanding renal pathophysiology
Exosomes are small membrane vesicles <80nm
diameter that originate within epithelial cells and
are secreted in the urine from all cells within the
nephron and urinary tract. They contain both cyto-
solic and membrane proteins and are easily
extracted from the urine in the ultracentrifugation
supernatant, and are thus a rich source of proteins
for proteomic analysis. Two hundred and ninety-five
proteins in the exosomes in normal urine have
been identified including many disease associated
proteins; aquaporin-2, polycystin-1, podocyin,
angiotensin-converting enzyme, thiazide-sensitive
Na–Cl cotransporter, epithelial sodium channel.93
Additional proteins have been found to be differen-
tially expressed in urinary exosomes of rats in
response to sodium loading, including alpha
2-microglobulin, solute carrier family 3, diphor-1,
meprin-1-a, H1-ATPase, and ezrin.94 This gives
great insight into the potential physiological pro-
cesses at play and with further analysis will lead to
better understanding of renal handling of sodium.
Identification of the urinary proteome in Dent’s
disease (a form of Fanconi syndrome) has led to fur-
ther insight into mechanisms of the proximal tubule
receptor-mediated endocytic pathway including a
reduction in vitamin and prosthetic group carriers
and an abundance of cytokines and complement
components present in the urine, which could
potentially lead to the development of directed
therapies.95
Although many of the sequenced renal disease
biomarkers do not immediately provide insight into
pathogenic mechanisms e.g. albumin and collagen
fragments, they may give information about disease-
specific protease activity within the kidney, such as
that resulting in ß2 microglobulin cleavage in acute
transplant rejection. Many proteins are high abun-
dance plasma proteins and appearance in the urine
is simply due to disruption of the glomerular base-
ment membrane, but certain fragments are charac-
teristic of particular diseases e.g. albumin fragments
specific for IgA nephropathy,66 diabetic nephropa-
thy,88 minimal change disease, FSGS, membranous
glomerulonephropathy42 and autosomal dominant
polycystic kidney disease96 reflecting tubular pro-
cessing of these proteins. The lack of collagen frag-
ments in diabetic nephropathy has led to the
speculation that reduced protease activity per se
contributes to disease pathology, resulting in
excess collagen and extracellular matrix deposi-
tion.88 Indeed the abundance of certain specific col-
lagen fragments has been shown to correlate with
matrix metalloprotease activity.97
Growth hormone (GH) has been uniquely identi-
fied in the urine of four patients with FSGS.98
Together with the findings of FSGS in transgenic
mice overexpressing GH, in patients with acrome-
galy and with pan-hypopituitism treated with GH
this suggests that GH has a role in the pathogenesis
in FSGS. Proteomics is likely to be able to contribute
towards many missing links in pathophysiological
models, especially as advances in technologies are
becoming available to detect the functional state of
proteins.
Other applications for urinary proteomics
in non-renal disease
Malignancies of the urinary tract in which proteins
are excreted into the urine have been a large focus
of recent study. Markers for prostate,99 bladder100
and renal cell tumours101 have been identified in
small studies and larger validation studies are under-
way to validate use in a clinical setting. Other appli-
cations for urinary proteomics include diagnosis of
interstital and bacterial cystitis,102 renal calculi,103
ureteropelvic junction obstruction,104 ovarian and
lung cancer,105,106 graft-versus-host disease27 and
coronary artery disease.107 Undoubtedly proteomics
will be applied to many other disease states and the
use of the urinary proteome will not be exclusive to
the diagnosis of renal pathology.
Limitations
Additional methodological problems to those dis-
cussed above include selection of controls, as all
quantitative approaches require reliable control
samples. In part, this can be addressed by pooling
samples from larger number of normal subjects.
Accurate information on the confounding effects of
factors such as age, gender, and diet on the urinary
proteome is not yet available; thus wherever
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possible these variables should be matched between
cases and controls.108 A working group has recently
concluded that it is not sufficient to compare the
disease in question with healthy individuals, given
that patients with diseases with similar metabolic,
clinical or biochemical profiles may have an indis-
tinguishable urinary proteome from that of the dis-
ease studied.109 This adds further complexities to
study design, but this caveat may apply only to
non-renal diseases given that it has already been
shown that it is recognized already that patients
with proteinuric renal disease including membra-
nous nephropathy, FSGS and minimal change
have distinct urinary proteomes.19
Another potential limitation to proteomics based
discovery of urinary biomarkers lies in the asso-
ciated cost; popularization of this approach will
inevitably lead to the need for acquisition of expan-
sive MS and associated instrumentation by clinical
laboratories.108 Ultimately, however, this could also
lower manufacturing costs and, especially if reli-
able, assays of disease biomarkers in urine will
lead to a reduction in renal biopsies, their associated
complications, and early intervention to reduce dis-
ease progression.
Conclusion
Recent developments in proteomic techniques
promise exciting insight into normal renal physiol-
ogy and renal disease processes, allowing precise
definition of the disease proteome. In turn this will
enable diagnosis, prognosis and prediction of
response to treatment of individuals. Considerable
developmental work is still required to refine the
standardization of urinary proteomics and to vali-
date earlier reports. There is the need for exploration
of diagnostic profiles in hitherto unexplored renal
diseases and in longitudinal analysis for evaluation
of treatment and assessment of prognosis. Expanding
knowledge in recent years and the rapidly advan-
cing field of proteomics will facilitate studies of
renal physiology and pathophysiology and ulti-
mately should make redundant the traditional
renal biopsy.
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